Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Sarcoma 2Rhabdomyosarcoma 2Medulloblastoma 2Uveal Melanoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Temozolomide 14Filgrastim 13Magnetic Resonance Spectroscopy 9Cyclophosphamide 7Carboplatin 7Peripheral Blood Stem Cell Transplantation 6Irinotecan 6Granulocyte Colony-Stimulating Factor 6Etoposide 6X-Rays 5Topotecan 5Thiotepa 5Phantoms, Imaging 5Busulfan 5Biopsy 5Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Melphalan 4Ifosfamide 4sargramostim 3palbociclib 3olaparib 3etoposide phosphate 3Surgical Procedures, Operative 3Paclitaxel 3ulixertinib 2trioctyl phosphine oxide 2tipifarnib 2tazemetostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Medulloblastoma × LY2940680 × Sarcoma × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT01697514 2013-08-27

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Eli Lilly and Company

Phase 1 Withdrawn
CNSSarcoma

Medulloblastoma, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡